Production (Stage)
Alzamend Neuro, Inc.
ALZN
$3.65
$0.092.53%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.06M | 3.22M | 3.08M | 3.48M | 4.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.21M | 5.83M | 7.37M | 9.94M | 12.39M |
| Operating Income | -4.21M | -5.83M | -7.37M | -9.94M | -12.39M |
| Income Before Tax | -4.23M | -5.85M | -7.39M | -9.95M | -12.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.23 | -5.85 | -7.39 | -9.95 | -12.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.23M | -5.85M | -7.39M | -9.95M | -12.40M |
| EBIT | -4.21M | -5.83M | -7.37M | -9.94M | -12.39M |
| EBITDA | -4.16M | -5.78M | -7.32M | -9.89M | -12.35M |
| EPS Basic | -27.71 | -59.99 | -96.22 | -133.33 | -168.30 |
| Normalized Basic EPS | -17.24 | -37.41 | -60.14 | -83.33 | -105.19 |
| EPS Diluted | -27.71 | -59.99 | -96.22 | -133.33 | -168.30 |
| Normalized Diluted EPS | -17.24 | -37.41 | -60.14 | -83.33 | -105.19 |
| Average Basic Shares Outstanding | 1.17M | 633.70K | 314.20K | 300.70K | 295.90K |
| Average Diluted Shares Outstanding | 1.17M | 633.70K | 314.20K | 300.70K | 295.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |